Literature DB >> 33718109

EZH2-miRNA Positive Feedback Promotes Tumor Growth in Ovarian Cancer.

Ting Liu1, Jian Cai1, Jing Cai1, Zehua Wang1, Liqiong Cai1.   

Abstract

Enhancer of zester homolog 2 (EZH2), a histone methyl transferase that mediates H3K27me3 through polycomb repressive complex 2 (PRC2), is overexpressed in ovarian cancer and promotes malignant proliferation. However, the underlying mechanism of maintaining high EZH2 expression remains elusive. Here we showed that microRNA(miRNA) inhibited EZH2 by binding to the 3'-UTR of EZH2 mRNA; conversely, EZH2 can inhibit miRNA expression. We confirmed that a feedback loop exists between EZH2 and miRNA that maintained EZH2 overexpression, thus promoting ovarian cancer proliferation in vivo and in vitro. We further explored that EZH2 inhibited miRNA expression through PRC2, as determined by CHIP (chromatin immunoprecipitation), and EZH2 decreased the expression of p21, p53, and RUNX3. These results suggest that EZH2 inhibits the expression of Et-miRNAs (EZH2-targeting miRNAs) through the H3K27me3 pathway, thus forming an EZH2-miRNA positive feedback loop that maintains the high expression of EZH2 and promotes the malignant proliferation of cancer cells by regulating the expression of cell proliferation-related proteins.
Copyright © 2021 Liu, Cai, Cai, Wang and Cai.

Entities:  

Keywords:  EZH2; H3K27me3; miRNA; ovarian cancer; positive feedback; proliferation

Year:  2021        PMID: 33718109      PMCID: PMC7947696          DOI: 10.3389/fonc.2020.608393

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  41 in total

1.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

Authors:  Chunxi Wang; Zhihui Liu; Chan-Wook Woo; Zhijie Li; Lifeng Wang; Jun S Wei; Victor E Marquez; Susan E Bates; Qihuang Jin; Javed Khan; Kai Ge; Carol J Thiele
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

2.  Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.

Authors:  Zhuo Li; Dehai Yu; Haijun Li; You Lv; Sijie Li
Journal:  Int J Oncol       Date:  2019-01-08       Impact factor: 5.650

Review 3.  p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy.

Authors:  Wafik S El-Deiry
Journal:  Cancer Res       Date:  2016-09-15       Impact factor: 12.701

Review 4.  Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements.

Authors:  Tiziana Tonini; Giuseppina D'Andrilli; Alfredo Fucito; Leonardo Gaspa; Luigi Bagella
Journal:  J Cell Physiol       Date:  2008-02       Impact factor: 6.384

5.  A double-negative feedback loop between EZH2 and miR-26a regulates tumor cell growth in hepatocellular carcinoma.

Authors:  Chunbo Zhuang; Pei Wang; Da Huang; Luming Xu; Xiaobei Wang; Lin Wang; Lihua Hu
Journal:  Int J Oncol       Date:  2016-01-13       Impact factor: 5.650

6.  The polycomb group protein EZH2 is involved in progression of prostate cancer.

Authors:  Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan
Journal:  Nature       Date:  2002-10-10       Impact factor: 49.962

7.  EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.

Authors:  Zhi-Yue Rao; Mu-Yan Cai; Guo-Fen Yang; Li-Ru He; Shi-Juan Mai; Wen-Feng Hua; Yi-Ji Liao; Hai-Xia Deng; Yang-Chao Chen; Xin-Yuan Guan; Yi-Xin Zeng; Hsiang-Fu Kung; Dan Xie
Journal:  Carcinogenesis       Date:  2010-07-28       Impact factor: 4.944

8.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

Authors:  Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

9.  EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.

Authors:  Bo Tang; Jian Du; Yang Li; Fang Tang; Zhenran Wang; Songqing He
Journal:  Med Oncol       Date:  2014-10-04       Impact factor: 3.064

10.  Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.

Authors:  Nasrin Rastgoo; Maryam Pourabdollah; Jahangir Abdi; Donna Reece; Hong Chang
Journal:  Leukemia       Date:  2018-04-24       Impact factor: 11.528

View more
  2 in total

1.  Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer.

Authors:  Yang Yi; Yanqiang Li; Chao Li; Longxiang Wu; Dongyu Zhao; Fuxi Li; Ladan Fazli; Rui Wang; Long Wang; Xuesen Dong; Wei Zhao; Kaifu Chen; Qi Cao
Journal:  Oncogene       Date:  2022-01-29       Impact factor: 8.756

Review 2.  Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network.

Authors:  Aixin Hao; Yunxuan Wang; Daniel B Stovall; Yu Wang; Guangchao Sui
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.